This workshop reported on the lessons learned from the evidence-based reviews on omega-3 fatty acids conducted by the Agency for Healthcare Research and Quality (AHRQ) and examined how this knowledge can be applied to researching the health effects of other bioactive food components.
AGENDA
Friday, April 1, 2005
Chairs: Leila G. Saldanha, PhD, RD and Paul M. Coates, PhD, Office of Dietary Supplements (ODS), National Institutes of Health (NIH)
1:00 pm	Opening Comments Leila G. Saldanha, PhD, RD, Scientific Consultant, ODS, NIH    Overview Bioactive Food Components Project (PDF, 131kB)
1:10 pm	NIH Needs for Evaluating Dietary Supplement Efficacy and Safety: Omega-3 Fatty Acids. Paul M. Coates, PhD, Director, ODS, NIH    NIH Needs for Evidence Reviews (PDF, 88kB)
1:20 pm	Overview of the Agency for Healthcare Research and Quality (AHRQ) Evidence-based Review Process Kenneth S. Fink, MD, MGA, MPH, Director, Evidence-based Practice Centers Program, Agency for Healthcare Research and Quality    AHRQ Evidence Review Process (PDF, 2404kB)
1:35 pm	Questions and Answers
1:45 pm	Lessons Learned: Evaluating Effects of Omega-3 Fatty Acids on Cardiovascular Disease Ethan Balk, MD MPH, Tufts-New England Medical Center, Boston, MA    Omega-3 and CVD, Lessons Learned (PDF, 167kB)
	Questions and Answers
2:30 pm	BREAK
2:50 pm	Lessons Learned: Evaluating Effects of Omega-3 Fatty Acids on Asthma, Eye-health, Mental-health, and Maternal & Child Health Howard Schachter, PhD, MA, University of Ottawa, Chalmers Research Group, Ontario, CANADA    Omega-3 Lessons Learned From Evidence Reviews (PDF, 1122kB)
	Questions and Answers
2:50 pm	Lessons Learned: Evaluating Effects of Omega-3 Fatty Acids on Immunological Disorders, Cancer, and Neurological Health Sydne Newberry, PhD, Southern California/RAND Corporation, Santa Monica, CA    Omega-3 and Immunological Disorders and Cancer, Lessons Learned (PDF, 954kB)
	Questions and Answers
4:10 pm	Panel Discussion Translation of lessons learned to researching the health effects of other bioactive food components. How can systematic reviews help identify gaps in research design and reporting of research results? Further, what has been learned through the evidence-based reviews on omega-3 fatty acids that could improve the quality of studies? When generally accepted biomarkers or surrogate end-points for evaluating the effects of a bioactive food component on a disease or health related-condition are not available, how can researchers go about selecting these end-points for in their research - this includes animal and human research? Are current models (in-vitro, in-vivo, animal, human) for evaluating the effects of a bioactive food component on a disease or health related-condition adequate? How do these models contribute toward arriving at policy decisions?
5:00 pm	ADJOURN

ACCESSIBILITY CONTACT US DISCLAIMER SITE MAP SITE POLICIES Office of Dietary Supplements National Institutes of Health Bethesda, Maryland 20892 USA Web: http://ods.od.nih.gov E-mail: [email protected]